Intratracheal colistin sulfate for BALB/c mice with early pneumonia caused by carbapenem-resistant Acinetobacter baumannii

Critical Care Medicine

Volumn 37, Issue 9, 2009, Pages 2590-2595

  Chiang, Shyh Ren ^a   Chuang, Yin Ching ^a   Tang, Hung Jen ^a   Chen, Chi Chung ^a   Chen, Chung Hua ^b   Lee, Nan Yao ^c   Chou, Chen His ^c   Ko, Wen Chien ^c  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b EN CHU KONG HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Carbapenem resistant Acinetobacter baumannii; Colistin sulfate; Intratracheal; Mice; Pneumonia

Indexed keywords

CARBAPENEM DERIVATIVE; CILASTATIN PLUS IMIPENEM; COLISTIN; SULBACTAM;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BAGG ALBINO MOUSE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; IN VIVO STUDY; LOBAR PNEUMONIA; LUNG; LUNG WEIGHT; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL;

EID: 69349095937     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181a0f8e1     Document Type: Article

References (29)

1. Quinn JP: Clinical problems posed by multiresistant nonfermenting Gram-negative pathogens. Clin Infect Dis 1998; 27: S117-S124
2. del Mar Tomas M, Cartelle M, Pertega S, et al: Hospital outbreak caused by a carbapenemresistant strain of Acinetobacter baumannii: Patient prognosis and risk-factors for colonisation and infection. Clin Microbiol Infect 2005; 11:540-546 (Pubitemid 40895153)
3. Landman D, Quale JM, Mayorga D, et al: Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: The preantibiotic era has returned. Arch Intern Med 2002; 162:1515-1520 (Pubitemid 34747486)
4. Chastre J: Infections due to Acinetobacter baumannii in the ICU. Semin Respir Crit Care Med 2003; 24:69-78
5. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, et al: Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36:1111-1118 (Pubitemid 36549630)
6. Kuo LC, Yu CJ, Lee LN, et al: Clinical features of pandrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Taiwan. J Formos Med Assoc 2003; 102:601-606 (Pubitemid 38081422)
7. Corbella X, Montero A, Pujol M, et al: Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 2000; 38: 4086-4095 (Pubitemid 32233209)
8. Falagas ME, Kasiakou SK: Colistin: The revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-1341
9. Michalopoulos A, Kasiakou SK, Mastora Z, et al: Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrugresistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005; 9:R53-R59
10. de Boer AH, Le Brun PP, van der Woude HG, et al: Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: Development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle. Eur J Pharm Biopharm 2002; 54:17-24
11. Falagas ME, Kasiakou SK: Toxicity of polymyxins: A systematic review of the evidence from old and recent studies. Crit Care 2006; 10:R27
12. Markou N, Apostolakos H, Koumoudiou C, et al: Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003; 7:R78-R83
13. Michalopoulos AS, Tsiodras S, Rellos K, et al: Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: The renaissance of an old antibiotic. Clin Microbiol Infect 2005; 11:115-121 (Pubitemid 40259694)
14. Levin AS, Barone AA, Penco J, et al: Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008-1011 (Pubitemid 29203530)
15. Montero A, Ariza J, Corbella X, et al: Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 2004; 54: 1085-1091 (Pubitemid 40136746)
16. Montero A, Ariza J, Corbella X, et al: Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002; 46: 1946-1952 (Pubitemid 34535219)
17. Ratjen F, Rietschel E, Kasel D, et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 2006; 57:306-311 (Pubitemid 43160174)
18. Kwa AL, Loh C, Low JG, et al. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005; 41:754-757 (Pubitemid 41170367)
19. Rouby JJ, Poete P, Martin de Lassale E, et al: Prevention of Gram-negative nosocomial bronchopneumonia by intratracheal colistin in critically ill patients. Histologic and bacteriologic study. Intensive Care Med 1994; 20:187-192
20. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing; 17th Informational Supplement. M100-S17. Wayne, PA, Clinical and Laboratory Standards Institute, 2007.
21. Wootton M, Holt HA, Macgowan AP: Development of a novel assay method for colistin sulphomethate. Clin Microbiol Infect 2005; 11:243-244 (Pubitemid 40352775)
22. Ho W, Furst A: Intratracheal instillation method for mouse lungs. Oncology 1973; 27:385-393
23. Elman M, Goldstein I, Marquette CH, et al: Influence of lung aeration on pulmonary concentrations of nebulized and intravenous amikacin in ventilated piglets with severe bronchopneumonia. Anesthesiology 2002; 97:199-206 (Pubitemid 34733941)
24. Kuo LC, Lai CC, Liao CH, et al: Multidrug-resistant Acinetobacter baumannii bacteraemia: Clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect 2007; 13: 196-198
25. Ioannidou E, Siempos II, Falagas ME, et al: Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis. J Antimicrob Chemother 2007; 60:1216-1226 (Pubitemid 350168316)
26. Falagas ME, Siempos II, Bliziotis IA, et al: Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: A meta-analysis of comparative trials. Crit Care 2006; 10:R123
27. Westerman EM, Le Brun PP, Touw DJ, et al: Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: A pilot study. J Cyst Fibros 2004; 1:23-28
28. U.S. Food and Drug Administration, Drug information: Colistimethate (marketed as Coly-Mycin M and generic products) information. Available at http://www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/ucm 118080.htm. Accessed July 12, 2009
29. Craig WA: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-12